Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. (Q53408220)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. (English)

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

1 reference

based on heuristic

inferred from title

author name string

Sung-Eun Lee

1

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Yoo-Jin Kim

2

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Seung-Ah Yahng

3

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Byung-Sik Cho

4

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Ki-Sung Eom

5

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Seok Lee

6

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Chang-Ki Min

7

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Hee-Je Kim

8

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Seok-Goo Cho

9

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Dong-Wook Kim

10

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Jong-Wook Lee

11

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Woo-Sung Min

12

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Chong-Won Park

13

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

publication date

2 October 2011

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

European Journal of Haematology

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

87

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

510-520

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

6

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Myelodysplastic syndromes--coping with ineffective hematopoiesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

The lower risk MDS patient at risk of rapid progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

A scheme for defining cause of death and its application in the T cell depletion trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01697.X

21 January 2018

Identifiers

10.1111/J.1600-0609.2011.01697.X

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

1 reference

Europe PubMed Central

14 May 2018

http://europepmc.org/abstract/MED/21883477

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53408220&oldid=1530810733"